Neuroprotective Strategies in Subarachnoid Hemorrhage

Primary Neuroprotective Intervention

• The American Heart Association recommends oral nimodipine 60 mg every 4 hours for 21 consecutive days to improve neurological outcomes in patients with aneurysmal subarachnoid hemorrhage, regardless of clinical grade 1, 2
• Nimodipine should be started within 96 hours of hemorrhage onset and continued for exactly 21 days, with consistent dosing without interruption to minimize delayed cerebral ischemia rates 1, 2, 3

Supportive Neuroprotective Measures

• The American College of Cardiology recommends maintaining euvolemia and normal circulating blood volume to prevent delayed cerebral ischemia, and avoiding prophylactic hypervolemia and triple-H therapy 1, 2, 5
• Correcting hypomagnesemia when present is associated with improved outcomes, but routine prophylactic IV magnesium infusion is not recommended for outcome improvement 4, 5

Interventions NOT Recommended as Neuroprotective Strategies

• The American Stroke Association does not recommend statins, tirilazad, endothelin-1 antagonists, aspirin, enoxaparin, or nicardipine IV as neuroprotective strategies due to lack of evidence or adverse effects 4, 5, 6

Rescue Therapies for Established DCI

• Inducing hypertension to increase cerebral blood flow is recommended when delayed cerebral ischemia develops despite nimodipine, with endovascular balloon angioplasty and intra-arterial vasodilator infusion also considered 1, 2, 4, 6

Emerging Strategies Requiring Further Evidence

• Anakinra, sulforaphane, remote ischemic preconditioning, and albumin administration are under investigation as potential neuroprotective strategies, with ongoing RCTs planned or in progress 6